Pediatrics. 2010 Feb;125(2):392-404. doi: 10.1542/peds.2009-3078. Epub 2010 Jan 25.
In the past half-century, hematopoietic stem cell transplantation has become standard treatment for a variety of diseases in children and adults, including selected hematologic malignancies, immunodeficiencies, hemoglobinopathies, bone marrow failure syndromes, and congenital metabolic disorders. There are 3 sources of allogeneic hematopoietic stem cells: bone marrow, peripheral blood, and umbilical cord blood; each has its own benefits and risks. Children often serve as hematopoietic stem cell donors, most commonly for their siblings. HLA-matched biological siblings are generally preferred as donors because of reduced risks of transplant-related complications as compared with unrelated donors. This statement includes a discussion of the ethical considerations regarding minors serving as stem cell donors, using the traditional benefit/burden calculation from the perspectives of both the donor and the recipient. The statement also includes an examination of the circumstances under which a minor may ethically participate as a hematopoietic stem cell donor, how the risks can be minimized, what the informed-consent process should entail, the role for a donor advocate (or some similar mechanism), and other ethical concerns. The American Academy of Pediatrics holds that minors can ethically serve as stem cell donors when specific criteria are fulfilled.
在过去的半个世纪中,造血干细胞移植已成为儿童和成人多种疾病的标准治疗方法,包括某些血液系统恶性肿瘤、免疫缺陷、血红蛋白病、骨髓衰竭综合征和先天性代谢疾病。异基因造血干细胞有 3 种来源:骨髓、外周血和脐带血;每种来源都有其自身的优势和风险。儿童通常是造血干细胞供者,最常见的是为其兄弟姐妹供者。由于与无关供者相比,移植相关并发症的风险降低,因此通常首选 HLA 匹配的同胞作为供者。本声明讨论了关于未成年人作为干细胞供者的伦理考虑,使用供者和受者的传统获益/负担计算来进行分析。本声明还探讨了未成年人在何种情况下可以合乎伦理地作为造血干细胞供者,如何将风险最小化,知情同意过程应包括哪些内容,供者倡导者(或类似机制)的作用以及其他伦理问题。美国儿科学会认为,当满足特定标准时,未成年人可以合乎伦理地作为干细胞供者。